Shandong Wohua Pharmaceutical Co., Ltd.
Symbool: 002107.SZ
SHZ
4.82
CNYMarktprijs vandaag
64.7237
Koers/Winst Verhouding
-0.2255
Koers/Winst Groei Verhouding
2.78B
MRK Kapitalisatie
- 0.00%
DIV Rendement
Shandong Wohua Pharmaceutical Co., Ltd. (002107-SZ) Jaarrekeningen
Balans
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 1553.9 | 401.1 | 278.3 | 326.8 | |||||||||||||||||||||
balance-sheet.row.short-term-investments | 0 | 0 | 0 | 0 | |||||||||||||||||||||
balance-sheet.row.net-receivables | 489.91 | 120.5 | 165.9 | 120.6 | |||||||||||||||||||||
balance-sheet.row.inventory | 580.07 | 149.1 | 146 | 165.9 | |||||||||||||||||||||
balance-sheet.row.other-current-assets | 31.94 | 2.3 | 9 | 7.2 | |||||||||||||||||||||
balance-sheet.row.total-current-assets | 2655.83 | 673 | 599.2 | 620.6 | |||||||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 1542.42 | 383.2 | 409.8 | 447.7 | |||||||||||||||||||||
balance-sheet.row.goodwill | 130.03 | 32.5 | 32.5 | 32.5 | |||||||||||||||||||||
balance-sheet.row.intangible-assets | 144.07 | 36.8 | 36 | 54.8 | |||||||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 274.1 | 69.4 | 68.5 | 87.3 | |||||||||||||||||||||
balance-sheet.row.long-term-investments | 73.91 | 18.4 | 19.1 | 0 | |||||||||||||||||||||
balance-sheet.row.tax-assets | 2.8 | 0.7 | 1.2 | 2.8 | |||||||||||||||||||||
balance-sheet.row.other-non-current-assets | 6.43 | 0 | 2.2 | 2.7 | |||||||||||||||||||||
balance-sheet.row.total-non-current-assets | 1899.66 | 471.7 | 500.8 | 540.5 | |||||||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||||||||||||
balance-sheet.row.total-assets | 4555.49 | 1144.7 | 1100 | 1161.1 | |||||||||||||||||||||
balance-sheet.row.account-payables | 223.67 | 52.9 | 45.3 | 26.8 | |||||||||||||||||||||
balance-sheet.row.short-term-debt | 4.7 | 2.7 | 1 | 2.8 | |||||||||||||||||||||
balance-sheet.row.tax-payables | 39.43 | 3.1 | 31.3 | 20.9 | |||||||||||||||||||||
balance-sheet.row.long-term-debt-total | -17.39 | -17.9 | 0.4 | 0.1 | |||||||||||||||||||||
Deferred Revenue Non Current | 72.77 | 17.9 | 20.7 | 23.8 | |||||||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 17.38 | - | - | - | |||||||||||||||||||||
balance-sheet.row.other-current-liab | 762.54 | 226.7 | 224.7 | 168.5 | |||||||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 75.16 | 5.3 | 26.8 | 28.1 | |||||||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||||||||||
balance-sheet.row.capital-lease-obligations | 1.01 | 0.4 | 0.4 | 0 | |||||||||||||||||||||
balance-sheet.row.total-liab | 1209.2 | 293.3 | 310.2 | 231.8 | |||||||||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||||||||||||
balance-sheet.row.common-stock | 2308.84 | 577.2 | 577.2 | 577.2 | |||||||||||||||||||||
balance-sheet.row.retained-earnings | 731.37 | 183.8 | 129.7 | 183.7 | |||||||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 167.6 | 44.2 | 39.6 | 59.8 | |||||||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 0 | 0 | 0 | |||||||||||||||||||||
balance-sheet.row.total-stockholders-equity | 3207.81 | 805.3 | 746.5 | 820.7 | |||||||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 4555.49 | 1144.7 | 1100 | 1161.1 | |||||||||||||||||||||
balance-sheet.row.minority-interest | 120.56 | 28.2 | 43.3 | 108.5 | |||||||||||||||||||||
balance-sheet.row.total-equity | 3328.36 | 833.5 | 789.8 | 929.3 | |||||||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 4555.49 | - | - | - | |||||||||||||||||||||
Total Investments | 73.91 | 18.4 | 19.1 | 0 | |||||||||||||||||||||
balance-sheet.row.total-debt | 4.74 | 2.7 | 1.4 | 2.8 | |||||||||||||||||||||
balance-sheet.row.net-debt | -1549.16 | -398.4 | -276.9 | -324 |
Kasstroomoverzicht
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 42.99 | 58.8 | 89.9 | 161.3 | |||||||||||||||||||||
cash-flows.row.depreciation-and-amortization | -0.12 | 33.2 | 35.3 | 33 | |||||||||||||||||||||
cash-flows.row.deferred-income-tax | 0 | 0.7 | 2.2 | 1.3 | |||||||||||||||||||||
cash-flows.row.stock-based-compensation | 0 | -18.9 | -2.2 | -1.3 | |||||||||||||||||||||
cash-flows.row.change-in-working-capital | 44.96 | 47.6 | 54.9 | -14 | |||||||||||||||||||||
cash-flows.row.account-receivables | 50.32 | 50.3 | -40.8 | 63.3 | |||||||||||||||||||||
cash-flows.row.inventory | -5.36 | -5.4 | 15.5 | -53.8 | |||||||||||||||||||||
cash-flows.row.account-payables | 0 | 2.6 | 78.1 | -24.8 | |||||||||||||||||||||
cash-flows.row.other-working-capital | 0 | 0 | 2.2 | 1.3 | |||||||||||||||||||||
cash-flows.row.other-non-cash-items | 64.7 | 7.8 | 5.1 | 19.8 | |||||||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 152.53 | 0 | 0 | 0 | |||||||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -2.21 | -2.7 | -6.8 | -19.1 | |||||||||||||||||||||
cash-flows.row.acquisitions-net | 0.06 | 0.1 | 1.2 | 0 | |||||||||||||||||||||
cash-flows.row.purchases-of-investments | 0 | 0 | 0 | 0 | |||||||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 0 | 0 | 0 | |||||||||||||||||||||
cash-flows.row.other-investing-activites | 0.06 | 0 | 0 | 0 | |||||||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | -2.15 | -2.6 | -5.6 | -19.1 | |||||||||||||||||||||
cash-flows.row.debt-repayment | 0 | 0 | -0.3 | -188.8 | |||||||||||||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 0 | 0 | |||||||||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | |||||||||||||||||||||
cash-flows.row.dividends-paid | 0 | 0 | -150.1 | -154.9 | |||||||||||||||||||||
cash-flows.row.other-financing-activites | -3.55 | -3.6 | -79 | -188.8 | |||||||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | -3.55 | -3.6 | -229.3 | -343.7 | |||||||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | -0.14 | -0.3 | 0 | 0 | |||||||||||||||||||||
cash-flows.row.net-change-in-cash | 147.9 | 122.8 | -49.7 | -162.6 | |||||||||||||||||||||
cash-flows.row.cash-at-end-of-period | 1551.56 | 401.1 | 276.5 | 326.2 | |||||||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 1403.67 | 278.3 | 326.2 | 488.9 | |||||||||||||||||||||
cash-flows.row.operating-cash-flow | 152.53 | 129.2 | 185.3 | 200.1 | |||||||||||||||||||||
cash-flows.row.capital-expenditure | -2.21 | -2.7 | -6.8 | -19.1 | |||||||||||||||||||||
cash-flows.row.free-cash-flow | 150.32 | 126.5 | 178.5 | 181 |
Rij winst-en-verliesrekening
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 882.86 | 894.3 | 1014.8 | 942.7 | |||||||||||||||||||||
income-statement-row.row.cost-of-revenue | 235.14 | 241.4 | 250.9 | 212.4 | |||||||||||||||||||||
income-statement-row.row.gross-profit | 647.73 | 652.9 | 763.9 | 730.3 | |||||||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||||||||||
income-statement-row.row.research-development | 37.89 | - | - | - | |||||||||||||||||||||
income-statement-row.row.selling-general-administrative | 19.49 | - | - | - | |||||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 491.95 | - | - | - | |||||||||||||||||||||
income-statement-row.row.other-expenses | 0.2 | -2.3 | 63 | 41.9 | |||||||||||||||||||||
income-statement-row.row.operating-expenses | 613.64 | 606.5 | 651.5 | 523.4 | |||||||||||||||||||||
income-statement-row.row.cost-and-expenses | 848.78 | 848 | 902.4 | 735.7 | |||||||||||||||||||||
income-statement-row.row.interest-income | 4.85 | 5.2 | 4.7 | 6.8 | |||||||||||||||||||||
income-statement-row.row.interest-expense | 0.03 | 0 | 0 | 4.7 | |||||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 491.95 | - | - | - | |||||||||||||||||||||
income-statement-row.row.total-other-income-expensenet | 5.22 | 8.3 | -1.5 | -2.7 | |||||||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||||||||||
income-statement-row.row.other-operating-expenses | 0.2 | -2.3 | 63 | 41.9 | |||||||||||||||||||||
income-statement-row.row.total-operating-expenses | 5.22 | 8.3 | -1.5 | -2.7 | |||||||||||||||||||||
income-statement-row.row.interest-expense | 0.03 | 0 | 0 | 4.7 | |||||||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 18.56 | 33.2 | 38.5 | 50.1 | |||||||||||||||||||||
income-statement-row.row.ebitda-caps | 48.25 | - | - | - | |||||||||||||||||||||
income-statement-row.row.operating-income | 34.94 | 46.3 | 112.3 | 192.7 | |||||||||||||||||||||
income-statement-row.row.income-before-tax | 40.17 | 54.6 | 110.8 | 190 | |||||||||||||||||||||
income-statement-row.row.income-tax-expense | 7.01 | 8 | 20.9 | 28.6 | |||||||||||||||||||||
income-statement-row.row.net-income | 42.99 | 58.8 | 107.4 | 163.4 |
Vaak gestelde vragen
Wat is Shandong Wohua Pharmaceutical Co., Ltd. (002107.SZ) totale activa?
Shandong Wohua Pharmaceutical Co., Ltd. (002107.SZ) totale activa is 1144706388.000.
Wat is de jaarlijkse omzet van de onderneming?
De jaarlijkse omzet is 401753358.000.
Wat is de winstmarge van de onderneming?
De bedrijfswinstmarge is 0.734.
Wat is vrije kasstroom van de onderneming?
De vrije kasstroom is {free_cash_flow}}.
Wat is de nettowinstmarge van de onderneming?
De nettowinstmarge is 0.049.
Wat is de totale omzet van de onderneming?
De totale opbrengst is 0.040.
Wat is Shandong Wohua Pharmaceutical Co., Ltd. (002107.SZ) nettowinst (netto-inkomen)?
De nettowinst is 58767086.000.
Wat is de totale schuld van het bedrijf?
De totale schuld is 2727141.000.
Wat zijn de bedrijfskosten?
De bedrijfsuitgaven zijn 606549582.000.
Wat is het kasstroomcijfer van het bedrijf?
Enretprise cash is 456686925.000.